Erytech Pharma SA

Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
  • TickerERYP
  • ISINFR0011471135
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas Thorez
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 05/07/2019

...

Cecile De Coincy ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Nicolas Thorez
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 07/05/2019

...

Oussema Denguir ...
  • Pierre Corby

Erytec Pharma : € 110m in cash at end-March 2019

>Q1 2019 figures - Yesterday evening Erytech published its financial results for Q1 2019. The operating loss deepened to € 13.26m (vs -€ 9.26m in Q1 2018) due mainly to: i/ the 19% increase in R&D spending to € 9.2m, reflecting progress in the Phase III trial in pancreatic cancer; and ii/ the rise in overheads to € 4.8m (+77% y-o-y) notably reflecting the costs stemming from the start-up of the new manufacturing unit in the US. The financial result in the period was p...

Oussema Denguir ...
  • Pierre Corby

Erytech Pharma : Trésorerie à 110 M€ à fin mars 2019

>Chiffres T1 2019 - Erytech publiait hier soir ses résultats financiers au titre du T1 2019, la perte opérationnelle se creuse à 13.26 M€ (vs -9.26 M€ au T1 2018) principalement du fait de i/ l’augmentation de 19% à 9.2 M€ des dépenses R&D traduisant l’avancement de la phase 3 dans le cancer du pancréas, ii/ la progression des frais généraux à 4.8 M€ (+77% yoy) notamment liés aux coûts engendrés par la mise en marche de la nouvelle unité de production aux USA. Le rés...

Cecile De Coincy ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Nicolas Thorez
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 07/05/2019

...

Oussema Denguir ...
  • Pierre Corby

Erytec Pharma : € 110m in cash at end-March 2019

>Q1 2019 figures - Yesterday evening Erytech published its financial results for Q1 2019. The operating loss deepened to € 13.26m (vs -€ 9.26m in Q1 2018) due mainly to: i/ the 19% increase in R&D spending to € 9.2m, reflecting progress in the Phase III trial in pancreatic cancer; and ii/ the rise in overheads to € 4.8m (+77% y-o-y) notably reflecting the costs stemming from the start-up of the new manufacturing unit in the US. The financial result in the period was p...

Oussema Denguir ...
  • Pierre Corby

Erytech Pharma : Trésorerie à 110 M€ à fin mars 2019

>Chiffres T1 2019 - Erytech publiait hier soir ses résultats financiers au titre du T1 2019, la perte opérationnelle se creuse à 13.26 M€ (vs -9.26 M€ au T1 2018) principalement du fait de i/ l’augmentation de 19% à 9.2 M€ des dépenses R&D traduisant l’avancement de la phase 3 dans le cancer du pancréas, ii/ la progression des frais généraux à 4.8 M€ (+77% yoy) notamment liés aux coûts engendrés par la mise en marche de la nouvelle unité de production aux USA. Le rés...

Anis Zgaya ...
  • Charles Lepetitpas
  • Christophe Chaput
  • François Maury
  • Georges Dieng
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 12/03/2019

...

Oussema Denguir ...
  • Pierre Corby

Erytec Pharma : € 134.4m in cash at end-2018

>2018 results - Yesterday evening, Erytech Pharma reported its figures for FY2018. Revenues rose to € 4.4m (vs € 3.3m) due to the increase in the research tax credit. The operating loss deepened to -€ 43.6m (vs -€ 30.9m in 2017) following the increase of: i/ 31% in R&D costs to € 33.4m, which underscored the acceleration in clinical businesses; and ii/ 66% in SG&A to € 14.6m, linked to the expansion of the US businesses. As such, the net loss deepened to -€ 38.2m (vs...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas Thorez
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 05/07/2019

...

Charles Lepetitpas ...
  • Christophe Chaput
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/12/2019

FFP is due to report its NAV at end-2018 on 18 March. We estimate this at € 148 per share, down 5% over 2018. Since the start of 2019, we estimate the rebound at 13% to € 167 per share. Buy recommendation maintained to benefit from dual leverage on the valuation: growth in NAV (the track record is excellent) and narrowing of the discount (historically high level of 43%). Target price lowered to € 131 vs € 136 previously. - ...

Emmanuel Matot ...
  • Jean-François Granjon
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 27/06/2018

...

Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 25/06/2018

...

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

Etude de l'AG du 27/06/2017

Concernant les diverses indemnités de départs convenues au bénéfice des dirigeants, bien que les montants maximum des indemnités soient en ligne avec le plafond de 12 mois de rémunération salariale (fixe + bonus annuel) fixé par Proxinvest, les motifs donnant droit au versement de celles-ci ne respectent pas la politique de Proxinvest qui en limite le versement à la seule hypothèse d’un départ contraint et lié à changement de contrôle. La résolution 17 relative à l’approbation des principes de détermination des éléments de rémunération des dirigeants pour l’exercice 2017 ne peut être soutenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch